Morphic Medical, Inc

Morphic Medical is a Boston-based MedTech company founded in 2003 specializing in innovative, minimally invasive device therapies for type 2 diabetes and obesity. The company's flagship product, RESET® therapy, is an endoscopically delivered device designed to address the underlying metabolic causes of type 2 diabetes and weight gain. RESET targets patients underserved by traditional pharmaceuticals and injections who are unsuitable for bariatric surgery, aiming to reduce HbA1c levels and body weight while improving glycemic control and cardiovascular risk profile. Currently investigational in the United States, RESET is undergoing clinical validation through the STEP-1 trial. Morphic Medical bridges the therapeutic gap between medical management and surgical intervention, offering a non-surgical alternative that leverages endoscopic delivery mechanisms to achieve durable metabolic benefits.